Genmab steps up for a $500M IPO haul, with its sights on a record-setting market cap
Genmab is right on the threshold now of completing the largest biotech listing — by market cap — that Renaissance Capital has seen for the past 20 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
